search
Back to results

NKG2D CAR-NK & r/rAML

Primary Purpose

AML

Status
Recruiting
Phase
Not Applicable
Locations
China
Study Type
Interventional
Intervention
NKG2D CAR-NK
Sponsored by
Zhejiang University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for AML focused on measuring CAR-NK, NKG2D

Eligibility Criteria

3 Years - 75 Years (Child, Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Age: ≥ 3 years old and ≤ 75 years old, male or female; Meet the diagnostic criteria for recurrent AML specified in the guidelines for diagnosis and treatment of acute myelogenous leukemia (relapse/refractory) in China (2017): leukemic cells reappear in peripheral blood or bone marrow MRD > 0.1% after complete remission (CR), including relapse after allogeneic hematopoietic stem cell transplantation or extramedullary leukemic cell infiltration. Meet the diagnostic criteria for refractory AML specified in the guidelines for diagnosis and treatment of acute myelogenous leukemia (relapse/refractory) in China (2017): Initial cases with failure of 2 lines of standard treatment; patients who relapsed within 12 months after consolidation intensification after CR; recurrence in 12 months and no respond to conventional chemotherapy; 2 or more recurrences; persistent extramedullarial leukemia; Patients currently have no effective treatment options, such as chemotherapy or allogeneic hematopoietic stem cell transplantation, or patients voluntarily choose to infuse NKG2D CAR-NK cells as the first treatment option; Physical status assessment (ECOG-PS) of the Eastern Oncology Collaborative Group is 0-2 points; Life expectancy ≥ 12 weeks from the time of enrollment; The main organs of the patient are well functioned: (1) cardiac function: no heart disease or coronary heart disease, the patient's cardiac function grade 1-2; (2) liver function: TBIL≦3ULN, AST≦2.5ULN, ALT≦2.5ULN; (3) Renal function: Cr≦1.25ULN; Flow cytometry check for NKG2D ligand expression on the surface of cancer cells as a reference for patient selection; The patient's peripheral superficial vein is accessible for IV insertion and blood draws; No other serious diseases that conflict with this protocol (e.g., autoimmune diseases, immunodeficiency, organ transplantation); No history of other malignant tumors;12. Women of childbearing age must be tested negative for pregnancy within 7 days, and subjects of childbearing age must use appropriate contraception during both the trial and for 3 months after the test; 13. Subjects have negative HIV, HBV, HCV, syphilis serology test results; 14. Written informed consent form must be signed by the patient or the patient's immediate family members before enrollment. Exclusion Criteria: Acute promyelocytic leukemia (Type M3); Patients with cardiac insufficiency, patients with liver and renal insufficiency; Patients with other malignant tumors need to be treated; Poorly controlled hypertension (systolic blood pressure >160 mmHg and/or diastolic blood pressure >90 mmHg) or clinically significant cardiovascular and cerebrovascular diseases such as cerebrovascular accident (within 6 months before signing the informed consent form), myocardial infarction (within 6 months before signing the informed consent), unstable angina, congestive heart failure, or severe arrhythmias that cannot be controlled with drugs or have a potential impact on research treatment; Patients suffering from other hematologic diseases (such as hemophilia, myelofibrosis, etc., which researchers consider unsuitable for enrollment); Patients with diffuse vascular internal coagulation; Patients with concomitant serious infection or other serious underlying medical condition; Patients with variable immunodeficiency and autoimmune diseases; Patients who have severe allergic diseases; Clinical symptoms of brain dysfunction or severe mental illness that can not understand or follow the research protocol; Have participated in clinical trials of other drugs within 4 weeks or within 21 days of surgery; Have received cell therapy in the previous 1 month; Have received hormonal drug therapy in the previous 14 days; Known human immunodeficiency virus (HIV) seropositivity or active hepatitis B or C infection or syphilis; Have received organ transplants (excluding stem cell transplant patients); Drug abuse, medical, psychological or social conditions that may interfere with a subject's participation in the study or evaluation of the results of the study; Pregnant or lactating women; Those who cannot be followed up as scheduled; Patients, who in the opinion of the investigator, have any clinical or laboratory abnormalities or compliance problems and are not suitable to participate in this clinical study.

Sites / Locations

  • The first affiliated hospital of medical college of zhejiang universityRecruiting
  • The first affiliated hospital of medical college of zhejiang universityRecruiting

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

rrAML

Arm Description

Outcomes

Primary Outcome Measures

DLT
Dose-Limiting Toxicity
MTD
Maximal Tolerable Dose

Secondary Outcome Measures

Full Information

First Posted
January 30, 2023
Last Updated
March 1, 2023
Sponsor
Zhejiang University
Collaborators
Hangzhou Cheetah Cell Therapeutics Co., Ltd
search

1. Study Identification

Unique Protocol Identification Number
NCT05734898
Brief Title
NKG2D CAR-NK & r/rAML
Official Title
NKG2D CAR-NK Cell Therapy for the Treatment of Patients With Relapsed and/or Refractory Acute Myeloid Leukemia
Study Type
Interventional

2. Study Status

Record Verification Date
March 2023
Overall Recruitment Status
Recruiting
Study Start Date
March 2023 (Anticipated)
Primary Completion Date
April 2024 (Anticipated)
Study Completion Date
September 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Zhejiang University
Collaborators
Hangzhou Cheetah Cell Therapeutics Co., Ltd

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
This trial will explore the maximum tolerated dose(MTD)of NKG2D CAR-NK cells in the treatment of relapsed or/and refractory AML in a dose-escalation manner, and observe the clinical safety and efficacy.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
AML
Keywords
CAR-NK, NKG2D

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
30 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
rrAML
Arm Type
Experimental
Intervention Type
Biological
Intervention Name(s)
NKG2D CAR-NK
Intervention Description
Lymphodepleting chemotherapy followed by NKG2D CAR-NK infusion
Primary Outcome Measure Information:
Title
DLT
Description
Dose-Limiting Toxicity
Time Frame
28 days
Title
MTD
Description
Maximal Tolerable Dose
Time Frame
28 days

10. Eligibility

Sex
All
Minimum Age & Unit of Time
3 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Age: ≥ 3 years old and ≤ 75 years old, male or female; Meet the diagnostic criteria for recurrent AML specified in the guidelines for diagnosis and treatment of acute myelogenous leukemia (relapse/refractory) in China (2017): leukemic cells reappear in peripheral blood or bone marrow MRD > 0.1% after complete remission (CR), including relapse after allogeneic hematopoietic stem cell transplantation or extramedullary leukemic cell infiltration. Meet the diagnostic criteria for refractory AML specified in the guidelines for diagnosis and treatment of acute myelogenous leukemia (relapse/refractory) in China (2017): Initial cases with failure of 2 lines of standard treatment; patients who relapsed within 12 months after consolidation intensification after CR; recurrence in 12 months and no respond to conventional chemotherapy; 2 or more recurrences; persistent extramedullarial leukemia; Patients currently have no effective treatment options, such as chemotherapy or allogeneic hematopoietic stem cell transplantation, or patients voluntarily choose to infuse NKG2D CAR-NK cells as the first treatment option; Physical status assessment (ECOG-PS) of the Eastern Oncology Collaborative Group is 0-2 points; Life expectancy ≥ 12 weeks from the time of enrollment; The main organs of the patient are well functioned: (1) cardiac function: no heart disease or coronary heart disease, the patient's cardiac function grade 1-2; (2) liver function: TBIL≦3ULN, AST≦2.5ULN, ALT≦2.5ULN; (3) Renal function: Cr≦1.25ULN; Flow cytometry check for NKG2D ligand expression on the surface of cancer cells as a reference for patient selection; The patient's peripheral superficial vein is accessible for IV insertion and blood draws; No other serious diseases that conflict with this protocol (e.g., autoimmune diseases, immunodeficiency, organ transplantation); No history of other malignant tumors;12. Women of childbearing age must be tested negative for pregnancy within 7 days, and subjects of childbearing age must use appropriate contraception during both the trial and for 3 months after the test; 13. Subjects have negative HIV, HBV, HCV, syphilis serology test results; 14. Written informed consent form must be signed by the patient or the patient's immediate family members before enrollment. Exclusion Criteria: Acute promyelocytic leukemia (Type M3); Patients with cardiac insufficiency, patients with liver and renal insufficiency; Patients with other malignant tumors need to be treated; Poorly controlled hypertension (systolic blood pressure >160 mmHg and/or diastolic blood pressure >90 mmHg) or clinically significant cardiovascular and cerebrovascular diseases such as cerebrovascular accident (within 6 months before signing the informed consent form), myocardial infarction (within 6 months before signing the informed consent), unstable angina, congestive heart failure, or severe arrhythmias that cannot be controlled with drugs or have a potential impact on research treatment; Patients suffering from other hematologic diseases (such as hemophilia, myelofibrosis, etc., which researchers consider unsuitable for enrollment); Patients with diffuse vascular internal coagulation; Patients with concomitant serious infection or other serious underlying medical condition; Patients with variable immunodeficiency and autoimmune diseases; Patients who have severe allergic diseases; Clinical symptoms of brain dysfunction or severe mental illness that can not understand or follow the research protocol; Have participated in clinical trials of other drugs within 4 weeks or within 21 days of surgery; Have received cell therapy in the previous 1 month; Have received hormonal drug therapy in the previous 14 days; Known human immunodeficiency virus (HIV) seropositivity or active hepatitis B or C infection or syphilis; Have received organ transplants (excluding stem cell transplant patients); Drug abuse, medical, psychological or social conditions that may interfere with a subject's participation in the study or evaluation of the results of the study; Pregnant or lactating women; Those who cannot be followed up as scheduled; Patients, who in the opinion of the investigator, have any clinical or laboratory abnormalities or compliance problems and are not suitable to participate in this clinical study.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Hu YongXian
Phone
+86-0571-87236476
Email
huyongxian2000@aliyun.com
Facility Information:
Facility Name
The first affiliated hospital of medical college of zhejiang university
City
Hangzhou
State/Province
Zhejiang
ZIP/Postal Code
310003
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Yongxian HU, MD
Phone
+86-0571-87236476
Email
huyongxian2000@aliyun.com
Facility Name
The first affiliated hospital of medical college of zhejiang university
City
Hangzhou
State/Province
Zhejiang
ZIP/Postal Code
310003
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
He Huang, MD
Phone
86-13605714822
Email
hehuangyu@126.com

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

NKG2D CAR-NK & r/rAML

We'll reach out to this number within 24 hrs